Abstract
Medullary breast carcinomas (MBCs) represent <5% of all invasive breast carcinomas and although these tumors show aggressive pathological features they are often associated with a more favourable outcome. It is also said to be particularly common in carriers of BRCA1 mutations. They are almost invariably negative for hormone receptors as well as Her-2/neu (‘triple negative’ phenotype). The prognosis for medullary carcinoma is better than for the ordinary invasive ductal carcinoma, a fact already apparent in the early reports on this tumor. We report a similar case in a 56 year old female with cytological, histological and immunohistochemical analysis of MBC.
Highlights
Medullary carcinomas both typical (MBC) and atypical (AMBC) are rare breast tumors that account for
Recent publications of breast cancer classification based on gene expression profile analyses indicate that medullary breast carcinomas can be considered part of the basal-like carcinoma spectrum made up of estrogen receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor 2 (HER-2/neu) negative cells (“triple-negative phenotype”) [5]
There are publications in which one may find that some MBC and AMBC are ER, PR and/or HER-2 positive, indicating the heterogeneity of this type of breast carcinomas [6,7]
Summary
Medullary carcinomas both typical (MBC) and atypical (AMBC) are rare breast tumors that account for
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
